Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Vincent P. Groot

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2102-3140; OpenAlex author ID A5010756211. Sources: OpenAlex.

Their work

Papers
52 (first author 12, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
149
Papers, trials and grants by year

2017: 2 papers · 2018: 12 papers · 2019: 7 papers · 2020: 2 papers · 2021: 3 papers · 2022: 7 papers · 2023: 4 papers · 2024: 5 papers · 2025: 4 papers · 2026: 6 papers

Papers 50 of 52

  1. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  2. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  3. Pancreatic ductal adenocarcinoma: Clinical trials to watch. Co-author DOI 10.1016/j.medj.2026.101268↗
  4. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-025-18639-1↗
  5. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-025-18791-8↗
  6. ASO Author Reflections: The Impact of Perioperative Treatment on Recurrence Treatment for Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18798-1↗
  7. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  8. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  9. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z↗
  10. ASO Author Reflections: Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Early Recurrence and Patient-Tailored Management. Co-author DOI 10.1245/s10434-024-16810-8↗
  11. Response to: Comment on "Dynamics of Serum CA 19-9 in Patients Undergoing Pancreatic Cancer Resection". Co-author DOI 10.1097/as9.0000000000000399↗
  12. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection. First author DOI 10.1097/sla.0000000000005977↗
  13. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  14. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  15. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  16. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. Co-author DOI 10.1016/j.ejso.2023.04.009↗
  17. Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy: An International Multicenter Study. Co-author DOI 10.1097/sla.0000000000005666↗
  18. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  19. Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence. Last author DOI 10.3390/jcm12237485↗
  20. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.09.004↗
  21. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.sopen.2022.07.007↗
  22. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. First author DOI 10.1097/sla.0000000000004093↗
  23. Response to Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis". First author DOI 10.1097/sla.0000000000005404↗
  24. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  25. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  26. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  27. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  28. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. Co-author DOI 10.1097/sla.0000000000003568↗
  29. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003570↗
  30. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  31. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  32. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.04.007↗
  33. Postoperative surveillance of pancreatic cancer patients. First author DOI 10.1016/j.ejso.2019.05.031↗
  34. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. Co-author DOI 10.1016/j.hpb.2018.12.002↗
  35. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002734↗
  36. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. First author DOI 10.1097/sla.0000000000002753↗
  37. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0197↗
  38. Lessons learned by features of pancreatic ductal adenocarcinoma and its tumor microenvironment. First author DOI 10.21037/atm.2019.01.32↗
  39. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. First author DOI 10.1002/jso.25288↗
  40. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.1016/j.ejrad.2018.07.010↗
  41. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. First author DOI 10.1016/j.hpb.2017.11.009↗
  42. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.jamcollsurg.2017.12.021↗
  43. Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jss.2017.08.023↗
  44. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002234↗
  45. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Co-author DOI 10.1097/sla.0000000000002672↗
  46. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. First author DOI 10.1097/sla.0000000000002925↗
  47. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. First author DOI 10.1245/s10434-017-6134-6↗
  48. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6558-7↗
  49. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1245/s10434-018-6820-z↗
  50. Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. Co-author DOI 10.18632/oncotarget.24713↗

Closest collaborators

The 25 strongest of 149 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Izaak Quintus Molenaar · 31 shared papers, 2017–2026 · strength 4.76
  2. Lois A. Daamen · 26 shared papers, 2017–2026 · strength 4.67
  3. Hjalmar C. van Santvoort · 24 shared papers, 2017–2026 · strength 3.85
  4. Jin Peng He · 24 shared papers, 2018–2026 · strength 2.59
  5. Marc G. Besselink · 18 shared papers, 2017–2026 · strength 2.49
  6. Christopher Lee Wolfgang · 22 shared papers, 2017–2026 · strength 2.43
  7. Martijn W.J. Stommel · 14 shared papers, 2019–2026 · strength 2.07
  8. Paul C. M. Andel · 9 shared papers, 2024–2026 · strength 1.87
  9. Vincent Erwin de Meijer · 12 shared papers, 2022–2026 · strength 1.85
  10. Bas Groot Koerkamp · 13 shared papers, 2019–2026 · strength 1.85
  11. Ignace H. J. T. de Hingh · 12 shared papers, 2022–2026 · strength 1.78
  12. Robert C. Verdonk · 11 shared papers, 2022–2026 · strength 1.71
  13. Richard Andrew Burkhart · 16 shared papers, 2018–2024 · strength 1.67
  14. Ammar A. Javed · 12 shared papers, 2018–2026 · strength 1.54
  15. Matthew John Weiss · 17 shared papers, 2018–2022 · strength 1.48
  16. Bert A. Bonsing · 9 shared papers, 2022–2026 · strength 1.45
  17. Iris W.J.M. van Goor · 8 shared papers, 2023–2026 · strength 1.45
  18. Georgios Gemenetzis · 15 shared papers, 2018–2023 · strength 1.37
  19. Alex B. Blair · 14 shared papers, 2018–2022 · strength 1.36
  20. Vincent B. Nieuwenhuijs · 9 shared papers, 2022–2026 · strength 1.35
  21. Sebastiaan Festen · 9 shared papers, 2022–2026 · strength 1.35
  22. Geert Kazemier M · 9 shared papers, 2022–2026 · strength 1.35
  23. A. Floortje van Oosten · 8 shared papers, 2019–2026 · strength 1.15
  24. Joseph R. Habib · 5 shared papers, 2023–2026 · strength 1.03
  25. Gert J. Meijer · 6 shared papers, 2022–2026 · strength 0.99

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.